Semaglutide and liraglutide are among the most effective, with semaglutide often leading to greater weight loss
Patients with controlled hyperthyroidism (TSH and free T4/T3 in target range on current therapy) often proceed with GLP-1 treatment under close medical supervision
In early phase 2a trials, it effectively improved glycemic control, increased post-meal insulin levels, and facilitated weight loss in participants with obesity and patients with T2DM [83]
United States Food and Drug Administration
Recommendations: A Collaborative Approach If you are considering or currently taking a GLP-1 inhibitor, especially if you have a pre-existing mental health condition, open communication with both your prescribing physician and your mental health provider is paramount
The researchers also discovered the quantity of GLP-1 medication users without FDA-approved indications increased from 0.21% in 2019 to 0.37% in 2023